Cemiplimab in Locally Advanced Basal Cell Carcinoma After Hedgehog Inhibitor Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cemiplimab in Locally Advanced Basal Cell Carcinoma After Hedgehog Inhibitor Therapy: An Open-Label, Multi-Centre, Single-Arm, Phase 2 Trial
Lancet Oncol 2021 May 14;[EPub Ahead of Print], AJ Stratigos, A Sekulic, K Peris, O Bechter, S Prey, M Kaatz, KD Lewis, N Basset-Seguin, ALS Chang, S Dalle, AF Orland, L Licitra, C Robert, C Ulrich, A Hauschild, MR Migden, R Dummer, S Li, SY Yoo, K Mohan, E Coates, V Jankovic, N Fiaschi, E Okoye, ID Bassukas, C Loquai, V De Giorgi, Z Eroglu, R Gutzmer, J Ulrich, S Puig, F Seebach, G Thurston, DM Weinreich, GD Yancopoulos, I Lowy, T Bowler, MG FuryFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.